Journal article

Poly(ADP-ribose) polymerase inhibition in acute lung injury. A reemerging concept

  • Szabo, Csaba Chair of Pharmacology, Section of Medicine, University of Fribourg, Fribourg, Switzerland
  • Martins, Vanessa Chair of Pharmacology, Section of Medicine, University of Fribourg, Fribourg, Switzerland
  • Liaudet, Lucas Service of Adult Intensive Care Medicine, University Hospital Medical Center, Lausanne University, Lausanne, Switzerland
Published in:
  • American Journal of Respiratory Cell and Molecular Biology. - 2020, vol. 63, no. 5, p. 571–590
English PARP1, the major isoform of a family of ADP-ribosylating enzymes, has been implicated in the regulation of various biological processes including DNA repair, gene transcription, and cell death. The concept that PARP1 becomes activated in acute lung injury (ALI) and that pharmacological inhibition or genetic deletion of this enzyme can provide therapeutic benefits emerged over 20 years ago. The current article provides an overview of the cellular mechanisms involved in the pathogenetic roles of PARP1 in ALI and provides an overview of the preclinical data supporting the efficacy of PARP (poly[ADP-ribose] polymerase) inhibitors. In recent years, several ultrapotent PARP inhibitors have been approved for clinical use (for the therapy of various oncological diseases): these newly-approved PARP inhibitors were recently reported to show efficacy in animal models of ALI. These observations offer the possibility of therapeutic repurposing of these inhibitors for patients with ALI. The current article lays out a potential roadmap for such repurposing efforts. In addition, the article also overviews the scientific basis of potentially applying PARP inhibitors for the experimental therapy of viral ALI, such as coronavirus disease (COVID-19)– associated ALI.
Faculté des sciences et de médecine
Médecine 3ème année
  • English
Biological sciences
License undefined
Persistent URL

Document views: 26 File downloads:
  • sza_ppi.pdf: 59